Trial Profile
Pharmacodynamic efffects of natalizumab on integrins such LFA-1 (CD11a), or chemokine receptors (CCR6, CXCR3) in multiple sclerosis patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 18 Dec 2015 New trial record